Since 1996, a highly active antiretroviral therapy (HAART) has been developed to treat Acquired immunodeficiency syndrome (AIDS) with impressive results. It consist in the combined prescription of several specific antiretroviral, which act together to prevent immunodeficiency virus 1 (HIV-1). However, the effectiveness of each set of antiretroviral varies depending on each patient, therefore the first step of the treatment for a specific patient is to find the more successful antiretroviral set. For patients not previously treated (naïve-patients), the HAART-regime initially tested is the initial NAÏVE (Abacanavir + Lamivudine + Raltegravir). Clinicians should monitor the drugs in the blood of patients to establish a lot of aspects of patient treatment, as malabsorption, drug interactions, and individual drug pharmacokinetics. This can help to determine the proper taking dose for a particular patient.

            A methodology based on micellar liquid chromatography was proposed to monitor the antiretroviral present in initial NAÏVE. Antiretroviral mixture were resolved using a 50 mM SDS mobile phase buffered at pH 7 running at 1 mL/min at room temperature, using a Kromasil C18 column (125×4.6 mm, 5mm particle size), UV detection at 214 nm. The finally suggested method was validated following the US Food and Drug Administration guidelines in terms of: linearity (0.5 to 50 ppm; r² > 0.9995), sensitivity (LODs of 1000 ng/mL), intra- and interday precision (< 8 %) and accuracy (< 7.5 %), and robustness (<5.1%). The method was used to monitor the level of antiretroviral in serum of AIDS patients from a local Hospital.             

Keywords: AIDS; Antiretroviral; Micellar liquid chromatography; Plasma; Validation  

Acknowledgements: This work was supported by Project P1.1B2012-36 del Pla de Promoció de la Investigació de la Universitat Jaume I.